New jab to fight severe asthma backed by NICE

GPs should refer patients with severe asthma to specialist care for treatment with omalizumab (Xolair), according to latest NICE guidance.

The NICE technology appraisal recommends the use of omalizumab for the treatment of severe persistent allergic asthma in adults and adolescents over the age of 12.

It is estimated that around 6,000 patients in the UK will be able to benefit from the drug, which is already available in Scotland.

Patients in England and Wales can expect the drug to become available within the next three months, with confirmation that the drug will be made available in Northern Ireland expected next month.

Omalizumab, which is given as a jab twice a month, should only be initiated if the patient has confirmation of IgE mediated allergy to a perennial allergen by clinical history and allergy skin testing.

GPs should only refer patients for the treatment if they have suffered two or more severe asthma attacks requiring hospital admission within the previous year, and a further two attacks which required treatment or monitoring in excess of the patient's usual regimen.

Treatment should be stopped if patients fail to show any adequate response after 16 weeks.

Glasgow GP Dr John Haughney, president of the International Primary Care Group, said: 'The drug can be life-transforming for asthmatic patients who have failed on treatments like oral steroids.

'Every practice is likely to have patients with severe asthma that will benefit from the drug.'

Dr Steve Holmes, chairman of the General Practice Airways Group and a GP in Somerset, said: 'It's important that GPs refer the patients that would benefit from the drug on to specialist centres to optimise its use.'

Neil Churchill, chief executive of the charity Asthma UK, described NICE's decision as a 'victory for people with severe allergic asthma'.

'Existing asthma treatments just do not work for around half a million people across the UK living with difficult to control asthma,' he said.

sanjay.tanday@haymarket.com

NICE guidance

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Practices handed one-month opt-out window as revamped network DES unveiled

Practices handed one-month opt-out window as revamped network DES unveiled

NHS England has unveiled a revamped DES package for 2020/21 confirming new targets,...

GPs delivered huge rise in face-to-face consultations in week before NHS England letter

GPs delivered huge rise in face-to-face consultations in week before NHS England letter

GPs delivered a huge increase in face-to-face appointments in the week before NHS...

RCGP facing legal action over stance on assisted dying

RCGP facing legal action over stance on assisted dying

The RCGP is facing legal action over its decision to remain opposed to assisted dying...

Medeconomics Live aims to help practices thrive under the new GP contract

Medeconomics Live aims to help practices thrive under the new GP contract

The one-day, virtual Medeconomics Live conference aims to provide practices with...

GPs face wave of abuse and complaints after NHS England face-to-face appointments claims

GPs face wave of abuse and complaints after NHS England face-to-face appointments claims

GP practices have faced a wave of abuse and complaints after a letter from NHS England...

Government denies plan to make GPs 'gatekeepers' of COVID-19 testing

Government denies plan to make GPs 'gatekeepers' of COVID-19 testing

The government has denied plans to make GPs 'gatekeepers' of the struggling COVID-19...